Craig-Hallum analyst Matt Hewitt maintained a Buy rating on Schrodinger (SDGR – Research Report) today. The company’s shares closed last Friday at $23.97.
Hewitt covers the Healthcare sector, focusing on stocks such as Avid Bioservices, Codexis, and Repligen. According to TipRanks, Hewitt has an average return of -4.0% and a 40.49% success rate on recommended stocks.
Currently, the analyst consensus on Schrodinger is a Moderate Buy with an average price target of $38.22.
SDGR market cap is currently $1.74B and has a P/E ratio of 46.19.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SDGR in relation to earlier this year. Last month, Kenneth Patrick Lorton, the EVP, CTO & COO, Software of SDGR bought 5,574.00 shares for a total of $24,191.16.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Schrodinger (SDGR) Company Description:
Schrödinger, Inc. provides chemical simulation software solutions to pharmaceutical industry. It operates through the Software and Drug Discovery business segments. The Software segment sells software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment offers diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. Schrödinger was founded by Richard A. Friesner, William A. Goddard, III and Murco Ringnalda in August 1990 and is headquartered in New York, NY.
